The Boston Globe

Business

In ALS drug, Biogen Idec sees a game changer

Biogen Idec Inc. Chief Executive Officer George Scangos was skeptical when he learned company researchers were pursuing a new treatment for Lou Gehrig’s disease. No one knows the cause of the illness that killed the famous baseball player more than 70 years ago, and no medicine for it has been shown to slow its advance for long.

Are you a home delivery subscriber?

Get FREE access as part of your print subscription

Start Here

Contact us for help

Comments